Bristol-Myers to invest in Compugen, collaborate in clinical trials

Bristol-Myers Squibb Co and Israel's Compugen said on Thursday they will collaborate in clinical trials for patients with advanced solid tumours.

The trials will evaluate the safety and tolerability of Compugen’s COM701, an investigational antibody, in combination with Bristol-Myers Squibb’s immune checkpoint inhibitor Opdivo.